NCT04835714View on ClinicalTrials.gov

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Solid Tumors, KRAS Mutation
Interventions
DRUG

BI 1701963

BI 1701963

DRUG

BI 3011441

BI 3011441

Trial Locations (4)

464-8681

Aichi Cancer Center Hospital, Aichi, Nagoya

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

135-8550

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY